Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Coller JK, Bowen JM, Ball IA, Wardill HR, van Sebille YZ, Stansborough RL, Lightwala Z, Wignall A, Shirren J, Secombe K, Gibson RJ.
Coller JK, et al.
Cancer Chemother Pharmacol. 2017 Feb;79(2):431-434. doi: 10.1007/s00280-016-3223-3. Epub 2016 Dec 23.
Cancer Chemother Pharmacol. 2017.
PMID: 28011980